Approximately 40–50% of melanomas harbor activating mutations of the RAS/RAF axis, including the V600E BRAF mutation in an oncogene known to be critical for melanoma proliferation and survival through its role in activating the RAF/MEK/ERK pathway [48]. This evidence concerns the gene MAP2K7 and melanoma.